Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial

Sabina Kersting, Julie Dubois, Kazem Nasserinejad, Johan A. Dobber, Clemens Mellink, Anne-Marie Van Der Kevie-Kersemaekers, Ludo M. Evers, Fransien de Boer, Harry R. Koene, John Schreurs, Marjolein van der Klift, Gerjo A. Velders, Ellen van der Spek, Hanneke M. Straaten, Mels Hoogendoorn, Michel van Gelder, Eduardus F. M. Posthuma, Hein P. J. Visser, Ilse Houtenbos, Cecile Idink, Djamila E. Issa, Ellen C. Dompeling, H.C.T. van Zaanen, Hendrik Veelken, Henriëtte Levenga, Lidwine W. Tick, Wim Terpstra, Sanne H. Tonino, Michelle Boyer, Mehrdad Mobasher, Mark‐David Levin, Arnon P. Kater